Replidyne axes licensing deal; ReNeuron raises funds;

> Replidyne has axed a licensing deal with Asubio Pharma and says it expects to take a charge of $4.1 million after failing to find a partner for faropenem. Report

> CV Therapeutics has pocketed a $10 million milestone payment. Release

> Boehringer Ingelheim and Geneart have forged a deal to collaborate on offering design and production services for DNA therapeutics and vaccines. Release

> Genzyme and Isis Pharmaceuticals have finalized their licensing deal for the cholesterol drug mipomersen. Release

> The stem cell research company Reneuron has raised £2.5 million from investors. Report

> New Jersey's planned $150 million stem cell research center has been put on ice as state leaders ponder how to proceed in the wake of voters' rejection of a $450 million stem cell initiative last year. New Jersey report

> India has been steadily building up the ranks of PhD-level scientists in the country, and now a new report shows the subcontinent has passed the U.K. in the number of scientists with doctorates. Report

> Is Pfizer consolidating its ad-agency work? Report

> More evidence that Asia is the place to be these days: Canada's Microbix Biosystems is plotting a $200 million flu vaccine plant in Hunan province. Report

> Costly cancer treatments are putting the U.K.'s NHS in quandary. Report

> Another generic deal that antitrust watchdogs love to hate: Barr Pharmaceuticals inked a deal to sell an "authorized generic" version of Bayer's birth control pill Yasmin. Report

And Finally... Families USA has crunched the numbers on NIH research grants, and says that several years of flat funding have crippled research efforts, damaged U.S. economic activity and threatens to pull the U.S. down from its leading role in global biomedical research efforts. NIH report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.